Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

Leonard, John P.; LaCasce, Ann S.; Smith, Mitchell R.; Noy, Ariela; Chirieac, Lucian R.; Rodig, Scott J.; Yu, Jinpu; Vallabhajosula, Shankar; Schöder, Heiko; English, Patricia A.; Neuberg, Donna; Martin, Peter; Millenson, Michael; Ely, Scott; Courtney, Ronan; Shaik, M. Naveed; Wilner, Keith D.; Randolph, Sophia; Abbeele, Annick D. Van den; Chen‐Kiang, Selina; Yap, Jeffrey T.; Shapiro, Geoffrey I.

doi:10.1182/blood-2011-10-388298

Cited by 271 publications

(198 citation statements)

References 43 publications

Supporting

Mentioning

197

Contrasting

Order By: Relevance

“…given for 14 consecutive days in 21-day cycles) PD0332991 is generally well tolerated with cytopenia being the main side effect. [46][47][48] Preliminary reports indicate that PD0332991 induces an 'unprecedented improvement of progression-free survival' of women with advanced breast cancer. 49 This compound received in 2013 the FDA 'Breakthrough Therapy' status allowing an accelerated clinical evaluation.…”

mentioning

confidence: 99%

The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes

et al. 2014

View full text Add to dashboard Cite

mentioning

confidence: 99%

The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes

et al. 2014

View full text Add to dashboard Cite

“…This compound showed significant activity in combination with fludarabine and rituximab or bortezomib in two phase I trials [58,59]. A direct CDK4/6 inhibitor, PD0332991, also achieved substantial responses and suggested clinical benefit in a subset of MCL patients [60].…”

Section: Cell Cycle/apoptosis Targeting Drugs and Othersmentioning

confidence: 99%

The current therapeutic scenario for relapsed mantle cell lymphoma

Ferrero

Dreyling

2013

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of reviewPatients with relapsing mantle cell lymphoma (MCL) still represent a demanding challenge for the hematooncologist. The dismal prognosis and the absence of generally accepted therapeutic standards hamper the clinical management of such cases. Moreover, the availability of many targeted approaches, in a field so far missing efficient salvage regimens, challenges current therapeutic algorithms in these patients. Recent findingsMolecular targeted drugs provide unprecedented response rates in relapsed and even chemorefractory MCL. Many phase II studies demonstrated impressive antilymphoma activity of compounds such as bortezomib, lenalidomide and temsirolimus, whereas ongoing phase III trials currently assess the 'real world' benefit and the impact on survival, both alone and in combination with chemotherapy or monoclonal antibodies. Recently, the Bruton's tyrosine kinase inhibitor ibrutinib, targeting the B-cell receptor cascade, showed impressive response rates and will be soon available in phase III trials. SummaryIn the present review we focus on the major therapeutic discoveries of the last few years to offer a practical algorithm to select the appropriate treatment in patients with relapsed MCL.

show abstract

“…Stable disease was manifested for 9 patients and dose limiting toxicity was myelosuppression. Another phase I study assessing mechanism of action, safety, and pharmacodynamic effects of PD 0332991 was performed in patients with mantle cell lymphoma using fluorine-18-labeled fluorodeoxyglucose ([ 18 F]FDG) and fluorothymidine ([ 18 F]FLT) positron emission tomography imaging (Leonard et al, 2008). Numerous phase II clinical trials of PD 0332991 are ongoing and currently recruiting patients: with advanced non-small cell lung cancer, with refractory solid tumors, with recurrent Rb positive glioblastoma, and with metastatic liposarcoma.…”

Section: Cdk Inhibitors For Cancer Therapymentioning

confidence: 99%